


IMPROVED PROTECTION AGAINST CERVICAL CANCER

PreTect® SEE

*Supports Cytology to increase
women's safety!*



**Be confident!
Focus on the
infection
that matters!**

**HPV mRNA E6/E7
16, 18, 45**


CLINICAL BENEFITS OF PreTect® SEE

- Qualitative detection of E6/E7 mRNA expression from HPV 16, 18, 45
- Intrinsic sample control ensuring sample adequacy
- High specificity, minimizing unnecessary interventions
- High PPV for CIN2+
- Enhanced identification of cervical adenocarcinoma
- Low positivity rate in general population
- CE-IVD kit

PreTect[®] SEE

Background

- Cervical cancer is caused by the continuous overexpression of the E6/E7 oncogenes from high-risk HPV types¹⁾
- 10-30% of women < 40 years have an HPV infection,²⁾ but the majority of these infections are harmless and resolve spontaneously³⁾
- HPV 16, 18 and 45 are aggressive types associated with rapid progression, accounting for > 90% of all cervical cancer worldwide in young women⁴⁾
- Despite well-established screening programs, the incidence of cervical cancer is increasing in young women^{5), 6)}
- 50% of women diagnosed with high-grade precancerous lesions are aged >35 years⁷⁾
- Cervical adenocarcinoma has increasing prevalence in recent decades and is clearly linked to HPV 16, 18, 45^{5), 8)}



References:

- 1) Zur Hausen H (2002) Nat Rev Cancer 2(5):342-350. Review
- 2) Preisler S et al (2013) PLOS ONE 8(3):e59765
- 3) Elfgrén et al (2000) Am J Obstet Gynecol 183(3):561-567
- 4) Munoz N et al (2004) Int J Cancer 111(2):278-285
- 5) www.kreftregisteret.no/globalassets/publikasjoner-ograpporter/livmorhalskreft/arsrapport/arsrapport-livmorhalsprogrammet-2015.pdf
- 6) NORDCAN; Cancer stat fact sheets; Norway- Cervix uteri: <http://www.dep.iarc.fr/NORDCAN/english/StatsFact.asp?cancer=212&country=578>
- 7) Tjalma W et al (2013) Int J Cancer 132 (4):854-867
- 8) Van der Horst J et al (2017) Cancer Med 6 (2):416-423

TEST INFORMATION

Individual HPV genotyping	E6/E7 mRNA HPV 16, 18 and 45
Intrinsic Sample Control (ISC)	Targeted mRNA from housekeeping gene
Sample type	Cervical samples
Storage media	PreTect TM (PreTect AS) PreservCyt/ThinPrep (Hologic) SurePath (BD Diagnostics)
Input material	Isolated Nucleic Acid (DNA/RNA)*
Technology	Real-time NASBA isothermal amplification (41°C) with four specific molecular beacon probes
Format	96-well PCR plate pre-filled with reagents n=94
Assay time	~ 150 minutes
Instrumentation:	Fluorescence reader / RT-PCR (CFX-96/QuantStudio5)

* DNA/RNA isolation reagents not included.

Key facts

- PreTect SEE: a qualitative CE-IVD kit identifying women with carcinogenic expression of high-risk HPV types, at risk for cervical cancer
- Co-testing with Pap smear improves the sensitivity of existing screening programs without excessive follow up burden
- High clinical specificity; low positive rate in the general population
- Ideal as a standalone test in low-income countries
- High capacity and low cost

DNA	mRNA
Double stranded	Single stranded
Stores genetic information	Decodes DNA info to produce proteins
Indicates presence of virus	Indicates gene activity

Contact us for further information!

PreTect AS

Ustadhagan 8 | N-3490 Klokkestua | Norway
Tel: +47 32 79 88 00 | www.prectect.no
E-mail: prectect@prectect.no

 **PRETECT** | by |  **MEL-MONT MEDICAL, Inc.**